BRIEF — OMass Therapeutics Announces $310 Million Series C Financing To Advance Portfolio Of Small Molecule Therapeutics In Endocrinology And Immunology

Oct 15 (Reuters) — Omass Therapeutics Announces $310 Million Series C Financing To Advance Portfolio Of Small Molecule Therapeutics In Endocrinology And Immunology Omass Therapeutics: Financing Co-led By Bain Capital Life Sciences, Forbion And Novo Holdings, Participation From Additional New, Existing Investors Source text:... Further company coverage: [ ] (Reuters.Briefs@thomsonreuters.com;)